Roche Acquires U.S.-Based PathAI in $750 Million Digital Pathology Deal
Roche Expands Digital Pathology Capabilities with PathAI Acquisition
Deal Overview and Financial Details
ZURICH, May 7 (Reuters) - Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further milestone payments of up to $300 million.
Background of Roche and PathAI Partnership
The acquisition builds on a five-year partnership between Roche and PathAI that was scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms.
Timeline and Integration
The deal is expected to close in the second half of 2026, and PathAI - based on Boston, Massachusetts - is due to become part of Roche's diagnostics division.
Strategic Impact on Digital Pathology
Strengthening Roche’s Market Position
Roche said the acquisition strengthens its position in digital pathology, which is helping to transform manual workflows into fully automated, AI-driven processes.
Potential Benefits for Cancer Diagnosis
Expert Commentary
"Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens," Matt Sause, CEO of Roche Diagnostics, said in a statement.
(Writing by Dave Graham, Editing by Friederike Heine)






